Statistiche di base
| CIK | 1420030 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Targeted Medical Pharma, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): May 14, 2019 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or organi |
|
| January 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): January 16, 2019 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or or |
|
| October 18, 2018 |
TRGM / Targeted Medical Pharma, Inc. FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-53071 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specifi |
|
| December 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): December 6, 2017 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or or |
|
| April 14, 2016 |
Targeted Medical Pharma (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015. Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-53071 TARGETED M |
|
| April 14, 2016 |
Complete Claims Processing, Inc. Exhibit 21 Complete Claims Processing, Inc. Amino Nutritionals, LLC |
|
| April 14, 2016 |
OPERATING AGREEMENT AMINO NUTRITIONALS, LLC Dated as of November 6, 2015 TABLE OF CONTENTS EX-10.34 2 ex10-34.htm Exhibit 10.34 OPERATING AGREEMENT OF AMINO NUTRITIONALS, LLC Dated as of November 6, 2015 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.1 Definitions 1 Section 1.2 Construction 5 ARTICLE II ORGANIZATION Section 2.1 Formation 5 Section 2.2 Name 5 Section 2.3 Registered Office; Registered Agent; Principal Office; Other Offices 5 Section 2.4 Purposes 6 Section 2.5 Powe |
|
| April 14, 2016 |
EX-10.35 3 ex10-35.htm Exhibit 10.35 PROMISSORY NOTE $100,000.00 Los Angeles, California December 1, 2015 FOR VALUE RECEIVED, Amino Nutritionals, LLC, a California Limited Liability Company (“Maker”), promises to pay YTR Capital, LLC (hereinafter, "Holder"), or order, in lawful money of the United States, the principal sum of One Hundred Thousand and 00/100 Dollars ($100,000.00), plus all accrued |
|
| March 31, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-13467 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| February 17, 2016 |
TRGM / Targeted Medical Pharma, Inc. / DERMA MEDICAL SYSTEMS INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 17, 2016 |
EXHIBIT 99.1 Pursuant to Rule 13d-1(k) (1) (iii) of Regulation 13D-G of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, the undersigned agree that the statement to which this Exhibit is attached is filed on behalf of each of them in the capacities set forth herein below. Date: February , 2016 DERMA MEDICAL SYSTEMS I |
|
| October 1, 2015 |
October 1, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, Dc 20549 Commissioners: We have read the statements made by Targeted Medical Pharma, Inc. under Item 4.01 of its Form 8-K dated October 1, 2015. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Targeted Medical Pharma, Inc. conta |
|
| October 1, 2015 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): September 28, 2015 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of (Commission (IRS |
|
| April 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-13467 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 3, 2015 |
EXHIBIT 17.1 February 26, 2015 To the Board of Targeted Medical Pharma, Inc. and its Chairman, Kerry Weems: I, William E. Shell, hereby resign from the Board of Targeted Medical Pharma, Inc., effective 11:59 a.m., on February 26, 2015, due to numerous disagreements and disputes with the Board of Directors, Officers and management, and significant corporate shareholders who have, and continue to co |
|
| March 3, 2015 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): February 26, 2015 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorpora |
|
| February 27, 2015 |
EX-10.1 2 ex10-1.htm THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH RE |
|
| February 27, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): February 23, 2015 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or o |
|
| February 11, 2015 |
TRGM / Targeted Medical Pharma, Inc. / DERMA MEDICAL SYSTEMS INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2015 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Pursuant to Rule 13d-1(k) (1) (iii) of Regulation 13D-G of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, the undersigned agree that the statement to which this Exhibit is attached is filed on behalf of each of them in the capacities set forth herein below. Date: February 11, 2015 |
|
| February 6, 2015 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D,C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): February 5, 2015 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of (Commissio |
|
| January 20, 2015 |
8-K 1 form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): January 13, 2015 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of in |
|
| January 20, 2015 |
EXHIBIT 10.3 Exhibit 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of January 13, 2015 (this “Agreement”), is among Targeted Medical Pharma, Inc., a Delaware corporation (the “Company”), Complete Claims Processing, Inc., a California corporation and wholly-owned subsidiary of the Company (the “Guarantor”), and the holder of the Company’s 4% Senior Secured Convertible Debenture due 3 ye |
|
| January 20, 2015 |
TARGETED MEDICAL PHARMA, INC. SECURITIES PURCHASE AGREEMENT EX-10.1 2 ex10-1.htm Exhibit 10.1 TARGETED MEDICAL PHARMA, INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Purchase Agreement”) made as of this 13th day of January 2015, between Targeted Medical Pharma, Inc., a Delaware corporation with offices located at 2980 Beverly Glen Circle, Suite 301, Los Angeles, CA 90077 (the “Company”), and the undersigned (the “Purchaser”). W |
|
| January 20, 2015 |
4% SENIOR SECURED CONVERTIBLE DEBENTURE DUE JANUARY 12, 2018 EXHIBIT 10.2 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EF |
|
| January 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): January 9, 2015 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or org |
|
| January 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): December 31, 2014 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or o |
|
| January 6, 2015 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): December 31, 2014 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorpora |
|
| June 11, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2014 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation) |
|
| May 20, 2014 |
Exhibit 99.1 |
|
| May 20, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2014 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction (Commissi |
|
| May 16, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-13467 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| April 30, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for use of the Commission |
|
| April 9, 2014 |
TRGM / Targeted Medical Pharma, Inc. / DERMA MEDICAL SYSTEMS INC. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 TARGETED MEDICAL PHARMA, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 876140104 (CUSIP Number) 12/23/2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| April 2, 2014 |
Exhibit 99.1 Exhibit 99.1 |
|
| April 2, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2014 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction (Commission (IRS |
|
| March 31, 2014 |
Targeted Medical Pharma ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013. Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-53071 TARGETED M |
|
| March 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2014 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation |
|
| March 11, 2014 |
Healthcare Executive Dr. Thomas Wenkart Joins Targeted Medical Pharma’s Board of Directors EXHIBIT 99.1 Company Contact: Targeted Medical Pharma Marcus Charuvastra | [email protected] (310) 474-9809 Investor Contact: ProActive Capital Group Jeff Ramson | [email protected] (646) 863-6893 Healthcare Executive Dr. Thomas Wenkart Joins Targeted Medical Pharma’s Board of Directors Los Angeles, March 5, 2014 –Targeted Medical Pharma, Inc. (OTCQB:TRGM) today announced that Dr. |
|
| March 11, 2014 |
EXHIBIT 99.2 Dr Thomas R Wenkart Dr. Thomas Wenkart attended Sydney University and graduated as a medico in 1968. He went to Royal Newcastle Hospital and entered General Practice and the world of medical computing in 1970. Dr. Wenkart acquired his first private hospital interest in 1978 and has since expanded Macquarie Hospital Services in Sydney and an interest in the Bega Valley Private Hospital |
|
| January 3, 2014 |
AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.2 3 v364108ex10-2.htm EXHIBIT 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (the “Amendment”) to the employment agreement, dated August 15, 2013 (the “Agreement”), by and between TARGETED MEDICAL PHARMA, INC, a Delaware corporation (“TMP”), and William B. Horne, an individual resident of California (“Executive”), is made and entered into this day of December 2013. For good and valuab |
|
| January 3, 2014 |
WC RECEIVABLES FUNDING, ASSIGNMENT AND SECURITY AGREEMENT (CA) EX-10.1 2 v364108ex10-1.htm EXHIBIT 10.1 WC RECEIVABLES FUNDING, ASSIGNMENT AND SECURITY AGREEMENT (CA) This Agreement is being entered into and shall be effective as of the day of , 20 (the “Effective Date”), by, between and among a company, with principal offices located at with an Employer Identification Number of (collectively “Medical Provider”), TARGETED MEDICAL PHARMA, INC. (collectively “T |
|
| January 3, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2014 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporatio |
|
| December 27, 2013 |
December 27, 2013 Via Federal Express Jeffery P. Riedler United States Securities and Exchange Commission Division of Corporation Finance 100 F Street Washington, DC 20549 Re: Targeted Medical Pharma, Inc. Form 10-K for the fiscal year ended December 31, 2012 Filed April 1, 2013 File No. 000-53071 Dear Mr. Riedler: Targeted Medical Pharma, Inc. (the “Company”, “it”, “we”, “us” or “our”) is transmi |
|
| October 7, 2013 |
Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporatio |
|
| September 9, 2013 |
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology September 2013 Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology September 2013 Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities of Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) . This document was prepared exclusively for the benefit and internal use of inve |
|
| September 9, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): September 9, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or o |
|
| August 22, 2013 |
EX-10.1 2 v353524ex10-1.htm EXHIBIT 10.1 EMPLOYMENT AGREEMENT This employment agreement (the “Agreement”) is effective as of August 15, 2013 between TARGETED MEDICAL PHARMA, INC, a Delaware corporation (“TMP”), and William B. Horne, an individual resident of California (“Executive”). RECITALS A. Executive has acquired special skills and abilities appropriate to and necessary for the role of Chief |
|
| August 22, 2013 |
Targeted Medical Pharma Selects William B. Horne as Chief Financial officer Media Contacts: PondelWilkinson George Medici | [email protected] Ron Neal | [email protected] (310) 279-5980 Investor Contacts: ProActive Capital Group Jeff Ramson | [email protected] (646) 863-6893 Targeted Medical Pharma Selects William B. Horne as Chief Financial officer Los Angeles, August 21, 2013, Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops a |
|
| August 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporatio |
|
| August 1, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation) |
|
| July 9, 2013 |
SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| July 3, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation) |
|
| July 3, 2013 |
PROFESSIONAL SERVICES and CONSULTING AGREEMENT PROFESSIONAL SERVICES and CONSULTING AGREEMENT This Agreement is being entered into and shall be effective as of the 28th day of June 2013 (the “Effective Date”), by, between and among TARGETED MEDICAL PHARMA, INC. |
|
| July 3, 2013 |
TARGETED MEDICAL PHARMA, INC. Common Stock Warrant EX-4.1 2 v349262ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE AND THE UNDERLYING SHARES OF COMMON STOCK HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES, THE SALE IS MADE |
|
| July 3, 2013 |
PROFESSIONAL SERVICES and CONSULTING AGREEMENT PROFESSIONAL SERVICES and CONSULTING AGREEMENT This Agreement is being entered into and shall be effective as of the 28th day of June 2013 (the “Effective Date”), by, between and among TARGETED MEDICAL PHARMA, INC. |
|
| July 3, 2013 |
WORKERS’ COMPENSATION RECEIVABLES FUNDING, ASSIGNMENT AND SECURITY AGREEMENT (CA) Exhibit 10.1 WORKERS’ COMPENSATION RECEIVABLES FUNDING, ASSIGNMENT AND SECURITY AGREEMENT (CA) This Agreement is being entered into and shall be effective as of the day of June 2013 (the “Effective Date”), by, between and among TARGETED MEDICAL PHARMA, INC. (collectively “TMP”), a Delaware corporation with principal offices located at 2980 Beverly Glen Circle, Suite 301, Los Angeles, CA 90077 with |
|
| June 12, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation) |
|
| June 12, 2013 |
Certified Public Accountants | 280 Kenneth Drive, Suite 100 | Rochester, New York 14623 | 585. |
|
| June 11, 2013 |
SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| May 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation) ( |
|
| April 23, 2013 |
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology April 2013 Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology April 2013 Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities of Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) . This document was prepared exclusively for the benefit and internal use of investor |
|
| April 23, 2013 |
TARGETED MEDICAL PHARMA, INC. 25,723,395 Shares PROSPECTUS Filed Pursuant to Rule 424(b)(3) SEC File No. 333-186667 TARGETED MEDICAL PHARMA, INC. 25,723,395 Shares This prospectus relates to the offer for sale of 25,723,395 shares of common stock, par value $0.001 per share, by the existing holders of the securities named in this prospectus, referred to as selling stockholders throughout this prospectus. The distribution of securities offered h |
|
| April 23, 2013 |
EX-99.1 2 v342167ex99-1.htm EXHIBIT 99.1 Investor Contacts: ProActive Capital Group Jeff Ramson, Founder & CEO [email protected] (646) 863-6893 Media Contacts: PondelWilkinson George Medici | [email protected] Ron Neal | [email protected] (310) 279-5980 Targeted Medical Pharma Pre-announces 2013 Unaudited Q1 Revenue -Company Reports Five Consecutive Quarters of Growth- Los Angeles, April |
|
| April 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation |
|
| April 19, 2013 |
Media Contacts: PondelWilkinson George Medici | [email protected] Ron Neal | [email protected] (310) 279-5980 Investor Contacts: PondelWilkinson Roger Pondel | Matt Sheldon [email protected] (310) 279-5975 Targeted Medical Pharma Announces Form S-1 Registration Statement Cleared by the SEC Los Angeles, April 18, 2013 – Targeted Medical Pharma, Inc. (OTCQB: TRGM) (the “Company”), a biotechno |
|
| April 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation |
|
| April 17, 2013 |
Targeted Medical Pharma, Inc. 2980 Beverly Glen Circle, Suite 301 Los Angeles, California 90077 April 17, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey P. Riedler Re: Targeted Medical Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-186667 Dear Mr. Riedler: Pursuant to Ru |
|
| April 12, 2013 |
TARGETED MEDICAL PHARMA, INC. 2980 BEVERLY GLEN CIRCLE, SUITE 301 LOS ANGELES, CA 90077 April 12, 2013 VIA EDGAR Jeffrey P. Riedler Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street Washington, DC 20549 Re: Targeted Medical Pharma, Inc. Registration Statement on Form S-1 Filed February 13, 2013 File No. 333-186667 Dear Mr. Riedler: Tar |
|
| April 12, 2013 |
As filed with the Securities and Exchange Commission on April 12, 2013 Registration No. |
|
| March 21, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporation |
|
| March 21, 2013 |
AMENDMENT NO.1 TO EMPLOYMENT AGREEMENT EX-10.1 2 v338720ex10-1.htm EXHIBIT 10.1 AMENDMENT NO.1 TO EMPLOYMENT AGREEMENT This Amendment No.1 (the "Amendment") dated March 18, 2013, to that certain Employment Agreement (the "Agreement"), dated November 28, 2011 between TARGETED MEDICAL PHARMA, INC. ("Employer") and DAVID SILVER, MD ("Executive"). Pursuant to Section 24(C) of the Agreement, Employer and Executive hereby agree to amend the |
|
| February 13, 2013 |
Targeted medical pharma Is assigned comprehensive Pharmaceutical BIlling PATENT Exhibit 99.1 Media Contacts: PondelWilkinson George Medici | [email protected] Ron Neal | [email protected] (310) 279-5980 Investor Contacts: PondelWilkinson Roger Pondel | Matt Sheldon [email protected] (310) 279-5975 Targeted medical pharma Is assigned comprehensive Pharmaceutical BIlling PATENT Los Angeles, February 12, 2013 – Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a |
|
| February 13, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-53071 20-5863618 (State or other jurisdiction of incorporat |
|
| February 13, 2013 |
As filed with the Securities and Exchange Commission on February 13, 2013 Registration No. |
|
| January 7, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): January 7, 2013 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or org |
|
| January 7, 2013 |
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology January 2013 Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology January 2013 Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities . Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) shall not have any responsibility for any such violations . This document was prepar |
|
| January 7, 2013 |
Media Contacts: PondelWilkinson George Medici | [email protected] Ron Neal | [email protected] (310) 279-5980 Investor Contacts: PondelWilkinson Roger Pondel | Matt Sheldon [email protected] (310) 279-5975 FIVE Targeted Medical Pharma Products LISTED on U.S. Dept. of Veterans Affairs’ Federal Supply Schedule (FSS) -Company’s prescription-only Medical Foods Now Available for Purchase by Fede |
|
| November 29, 2012 |
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology November 2012 EX-99.1 2 v329419ex99-1.htm EXHIBIT 99.1 Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology November 2012 Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities . Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) shall not have any responsibility for any |
|
| November 29, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): November 29, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or o |
|
| November 28, 2012 |
FORM 144/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144/A NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker. 1(a) NAME OF ISSUER (b) IRS IDENT. NO. |
|
| November 20, 2012 |
Form 144 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker. 1(a) NAME OF ISSUER (b) IRS IDENT. NO. (c) |
|
| November 7, 2012 |
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology SoCal Bio Presentation – November 2012 Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities . Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) shall not have any responsibility for any such violations |
|
| November 7, 2012 |
8-K 1 v3277338k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): November 7, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other |
|
| November 1, 2012 |
Exhibit 10.1 Targeted Medical Pharma, Inc. 2980 Beverly Glen Circle Suite 301 Los Angeles, California 9077 July 20, 2012 AFH Holding and Advisory, LLC 9595 Wilshire Boulevard Suite 700 Beverly Hills, California 90212 Gentlemen: Reference is hereby made to the Letter of Intent, dated January 25, 2011, by and between Targeted Medical Pharma, Inc. (“the Company”) and AFH Holding and Advisory, LLC (“A |
|
| November 1, 2012 |
TRGM / Targeted Medical Pharma, Inc. / AFH Holding & Advisory, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 5) Under the Securities Exchange Act of 1934 Targeted Medical Pharma, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 876140104 (CUSIP Number) Amir Heshmatpour 9595 Wilshire Blvd. Suite 700 Beverly Hills, CA 90212 (310) 492-9898 (Name, Address and Telep |
|
| November 1, 2012 |
AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF REORGANIZATION Exhibit 10.3 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF REORGANIZATION AMENDMENT NO. 2 TO THE AGREEMENT AND PLAN OF REORGANIZATION (this “Amendment”) made effective as of August 13, 2012 by and between AFH Holding and Advisory, LLC (“AFH”), Targeted Medical Pharma, Inc. (“Targeted”), William E. Shell, MD (“Shell”), the Estate of Elizabeth Charavustra (the “Estate”) and Kim Giffoni (“Giffoni”). WITNE |
|
| November 1, 2012 |
EX-10.2 3 v327181ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 Targeted Medical Pharma, Inc. 2980 Beverly Glen Circle Suite 301 Los Angeles, California 9077 July 25, 2012 AFH Holding and Advisory, LLC 9595 Wilshire Boulevard Suite 700 Beverly Hills, California 90212 Gentlemen: Reference is hereby made to the letter agreement (the “Letter Agreement”), dated as of the date hereof, by and between Targeted Med |
|
| November 1, 2012 |
Exhibit 10.5 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Security Agreement”), is made as of July 20, 2012, by and between Targeted Medical Pharma, Inc., a Delaware corporation, having an address at 2980 Beverly Glen Circle, Suite 301, Los Angeles, CA 90077 (the “Obligor” or “Company”), and AFH Holding and Advisory, LLC, a Delaware limited liability company, having an address at 9595 Wilshir |
|
| November 1, 2012 |
SECURED CONVERTIBLE PROMISSORY NOTE Exhibit 10.4 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES AC |
|
| October 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): October 1, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or org |
|
| August 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): August 16, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or o |
|
| August 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): August 6, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or orga |
|
| August 7, 2012 |
AMENDMENT NO. 1 TO AMENDED AND RESTATED BY-LAWS OF TARGETED MEDICAL PHARMA, INC. Exhibit 3.2 AMENDMENT NO. 1 TO AMENDED AND RESTATED BY-LAWS OF TARGETED MEDICAL PHARMA, INC. Article II, Section 2.2 of the Amended and Restated Bylaws of Targeted Medical Pharma, Inc. (the ”Corporation”) hereby is amended and restated in its entirety as follows: ARTICLE II BOARD OF DIRECTORS Section 2.2 Number, Term of Office and Election. The Board of Directors shall consist of not fewer than se |
|
| August 7, 2012 |
SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TARGETED MEDICAL PHARMA, INC. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TARGETED MEDICAL PHARMA, INC. TARGETED MEDICAL PHARMA, INC., a corporation existing under the laws of the State of Delaware, does hereby certify as follows: 1. The name of the corporation (the “Corporation”) is Targeted Medical Pharma, Inc. 2. The original Certificate of Incorporation of the Corporation was filed in the office |
|
| August 7, 2012 |
HEALTHCARE INDUSTRY LEADER Kerry Weems Joins Targeted medical Pharma’s Board Of Directors Exhibit 99.1 Investor Contacts: PondelWilkinson Roger Pondel | Matt Sheldon [email protected] (310) 279-5975 Media Contacts: George Medici | [email protected] Ron Neal | [email protected] (310) 279-5980 HEALTHCARE INDUSTRY LEADER Kerry Weems Joins Targeted medical Pharma’s Board Of Directors Los Angeles, August 7, 2012 –Targeted Medical Pharma, Inc., a specialty pharmaceutical company that |
|
| July 18, 2012 |
Targeted medical pharma Issues letter to shareholders EXHIBIT 99.1 Investor Contacts: PondelWilkinson Roger Pondel | Matt Sheldon [email protected] (310) 279-5975 Media Contacts: George Medici | [email protected] Ron Neal | [email protected] (310) 279-5980 Targeted medical pharma Issues letter to shareholders Los Angeles, July 17, 2012 –Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription |
|
| July 18, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v3188258k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): July 17, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jur |
|
| July 17, 2012 |
SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| June 29, 2012 |
SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| June 29, 2012 |
TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2010 Exhibit 99.1 TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2010 CONTENTS PAGE Report of Registered Public Accounting Firm 2 Consolidated Balance Sheets 3 Consolidated Statements of Income 4 Consolidated Statements of Shareholders' Equity 5 Consolidated Statements of Cash Flows 6 Notes to Consolidated Financial Statements 7 REPORT OF INDEPENDENT REGIS |
|
| June 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): June 29, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or org |
|
| June 15, 2012 |
Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): June 11, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or organ |
|
| June 5, 2012 |
TARGETED MEDICAL PHARMA, INC. 2980 Beverly Glen Circle, Suite 301 Los Angeles, California 90077 June 5, 2012 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Filing Desk Re: Targeted Medical Pharma, Inc. Registration Statement on Form S-1 (File No. 333-172243), filed on February 14, 2011, As amended on Form S-1/A Amen |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2011 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report o |
|
| March 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest event Reported): March 21, 2012 TARGETED MEDICAL PHARMA, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-53071 20-5863618 (State or other jurisdiction of incorporation or orga |
